Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.


Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.


You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

Know Labs Unveils Non-Invasive Glucose Monitor Prototype

Here is a brief preview of this blast: Know Labs announced it has completed the prototype build for its first generation portable non-invasive glucose monitor. According to the press release, Gen 1 incorporates Know Labs’ Bio-RFID sensor in a portable device (view image below). Recall, on May 31, 2023, Know Labs announced the publication of a report showing the accuracy of its non-invasive Bio-RFID blood glucose reading in combination with algorithm optimization using a light gradient-boosting machine (lightGBM) machine learning model which demonstrated that BG levels measured by Bio-RFID sensors showed a 12.9% MARD when compared to the Dexcom G6 (previous FENIX insight). Below, FENIX provides brief thoughts on the regulatory path forward for the Gen 1 device.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.